Furthermore, after monotherapy with BRAF inhibitors was first trialled in melanoma, the eruptive development of other MAPK-driven neoplasms (most commonly RAS mutant keratoacanthomas and cutaneous squamous cell carcinomas) was reported (8). Here, BRAF is linked to keratoacanthoma.